Egypt leads presidential health initiatives, ranks high in national performance metrics
The Red Sea Governorate continues to distinguish itself in the implementation of presidential health initiatives, achieving advanced rankings nationwide. This comes in line with the directives of Khaled Abdel Ghaffar, Minister of Health, and underscores the state's commitment to improving the quality of healthcare services provided to citizens.
Ismail Al-Arabi, Undersecretary of the Ministry of Health and Population in the Red Sea, affirmed that the Health Directorate has achieved exceptional results. Recent performance evaluations revealed the governorate's leading positions in several initiatives. Most notably, the Women's Health Support Initiative saw the Red Sea Governorate secure first place nationally. This achievement is attributed to dedicated efforts in examination, awareness, and early disease detection, reflecting the commitment of medical teams and the effectiveness of fieldwork.
The Undersecretary of Health added that the Red Sea Governorate ranked third in the Maternal and Fetal Care Initiative, demonstrating the quality of care provided to pregnant women and success in early detection of mother-to-fetus transmitted diseases. Similarly, in the Early Detection of Cancer Tumors Initiative and the distribution of "FIT" samples, the governorate achieved fourth place among governorates in terms of quality of implementation and coverage of target groups. Overall, in the general classification of health initiatives' performance, the Red Sea Governorate secured fifth place nationwide, an accomplishment reflecting seriousness and discipline in executing presidential health directives.
For the Chronic Diseases and Early Detection Initiative, the governorate ranked seventh with an achievement rate of 98%, reaching 1036 cases out of the monthly target of 1062 cases. This underscores the efficiency of the work system in reaching targeted populations. Al-Arabi emphasized that these successes are the fruit of effective cooperation and coordination between medical and administrative teams, under the supervision of Dr. Basma Yahya, the initiatives' coordinator in the governorate.
The Undersecretary of Health clarified that Ahmed Galal, Director of Primary Care Administration, Shireen Magdy, Director of Motherhood and Childhood Administration, and Nurse Hanaa Mohamed, Nursing Supervisor for the Initiatives, participated meticulously in the implementation of these initiatives.
He further stressed that these results reflect the spirit of teamwork and the dedication of medical and administrative staff in implementing the Ministry of Health's plans and the political leadership's directives.
He affirmed the continuation of efforts to ensure the provision of integrated healthcare services worthy of the people of the Red Sea Governorate, extending thanks to all work teams and calling for continued commitment and increased efforts to achieve further successes in developing the healthcare system.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily News Egypt
4 hours ago
- Daily News Egypt
Egypt, India's BDR Group in talks to establish biologics, cancer drug facility
Egypt's Minister of Health, Khaled Abdel Ghaffar, met Tuesday with Dharmesh Shah, Chairperson and Managing Director of India's BDR Group, to discuss plans for a joint pharmaceutical venture, including the establishment of a local facility for the production of biologics and cancer medications, according to a statement from the Ministry of Health. The meeting also included Gamal El-Leithy, CEO of Future Pharmaceuticals Industries (FPI) and head of Egypt's Chamber of Pharmaceutical Industry, as well as senior officials Hisham Stait, Head of the Unified Procurement Authority, and Ali El-Ghamrawy, Chairperson of the Egyptian Drug Authority. Minister Abdel Ghaffar emphasized Egypt's strategic goal of localizing pharmaceutical manufacturing and transferring advanced technology to enhance national drug security. He underscored the importance of partnering with global industry leaders to reduce reliance on imports and ensure access to affordable, high-quality medicines for Egyptian patients. Ministry spokesperson Hossam Abdel Ghaffar noted that the proposed facility aims to significantly lower the country's import bill for specialty drugs—particularly oncology treatments—which place considerable pressure on the national budget and foreign currency reserves. The project is expected to provide a stable, cost-effective supply of essential biologic therapies. The minister called for the swift implementation of the initiative, instructing relevant stakeholders to set a clear timeline and expedite the registration of products through the Egyptian Drug Authority. BDR Group representatives shared insights into the company's expertise in producing oncology drugs and biologics, highlighting successful international projects that have enhanced healthcare outcomes while reducing costs.
Daily News Egypt
a day ago
- Daily News Egypt
Egypt's Supreme Organ Transplant Committee strengthens oversight, standards
Egypt's Supreme Committee for Organ Transplantation convened to assess the country's transplant program, reinforce regulatory oversight, and align practices with international medical standards, the Ministry of Health announced Monday. Health Ministry spokesperson Hossam Abdel Ghaffar stated that the meeting addressed several key areas, including the formation of specialized subcommittees, strategies to counter misinformation on social media, and the introduction of a new regulation limiting transplant approval validity to one year. Under this regulation, each transplant program must be affiliated with a single licensed medical facility. According to 2024 data, the committee issued 1,614 transplant approvals—1,194 for kidneys and 420 for livers. That year, 1,271 transplants were performed: 764 kidney and 234 liver transplants for Egyptian patients, and 188 kidney and 85 liver transplants for non-Egyptians. So far in 2025, 907 approvals have been issued (677 kidney, 230 liver). Egypt currently has 40 licensed transplant centers operating across public, university, private, police, and military hospitals. In 2024, the committee renewed licenses for 14 liver and 18 kidney centers and approved five new hospitals under licensing decision No. 124. Random inspections of transplant facilities will continue, with immediate corrective actions enforced in cases of non-compliance. The committee also reviewed mortality and morbidity data and discussed the governance of transplant procedures. One notable case involved a 62-year-old father successfully donating a kidney to his son after the procedure was cleared under Cabinet Decree No. 74 of 2023 and in accordance with Egypt's Organ Transplant Law No. 5 of 2010. Officials highlighted the urgent need for updated legislation and tighter oversight to safeguard the rights of both donors and recipients. Established in 2023 under Decree No. 4497 and chaired by Minister of Health Dr. Khaled Abdel Ghaffar, the Supreme Committee includes leading medical figures, such as world-renowned heart surgeon Sir Magdi Yacoub. It is supported by dedicated scientific, ethical, and licensing subcommittees to ensure that Egypt's transplant practices meet global medical and ethical benchmarks.
Egypt Independent
5 days ago
- Egypt Independent
Health Ministry reviews Fitch agency's report on Egypt's achievements in pharmaceutical industry
The Ministry of Health and Population expressed appreciation for the report issued by Fitch Ratings in August 2025, which praised the strategic steps Egypt has taken to strengthen the pharmaceutical industry. The report confirmed that the comprehensive economic reforms and wide-ranging regulatory updates implemented by the Egyptian state have contributed to creating an attractive investment environment, enhancing Egypt's position as a leading regional hub for the pharmaceutical industry in the Middle East and North Africa region. The report highlighted that these reforms attracted major global companies to the Egyptian market. The report also lauded significant regulatory transformations, topped by the reduction of drug registration periods from 3-5 years to between two and six months, thus enabling global companies to accelerate product launches and increase registration applications. It explained that the Egyptian market continues to promote local manufacturing and technology transfer despite challenges linked to investment in research and development. It noted that in 2024, the Egyptian government signed three financing agreements with the European Union worth 36 million euros to support vaccine manufacturing and scientific research development. The report also praised the legal framework regulating clinical trials, including Law No. 214 of 2020 and its executive regulations No. 927 of 2022, which improve ethical oversight and participant protection. The report addressed health and population achievements related to medicine demand, noting Egypt's efforts to confront challenges associated with population growth and non-communicable disease prevalence through presidential initiatives for early detection and awareness. It also commended sustainable achievements in combating infectious diseases, highlighting the World Health Organization's declaration of Egypt as free from malaria, measles, and rubella, along with notable progress toward eliminating hepatitis C and B. Furthermore, the report underscored national efforts to combat diabetes through screening, early diagnosis campaigns, updating treatment guidelines, conducting the Stepwise survey, and distributing 3,000 HbA1c testing devices to primary healthcare units, ensuring unified care standards based on scientific evidence. It pointed to a noticeable decline in fertility rates from 3.44 births per woman in 2015 to 2.10 births in 2023, reflecting the expansion of reproductive health services, increased education rates, and women's participation in the labor market. Regarding cancer, the report stated that early detection initiatives, notably the President's initiative to support Egyptian women's health launched in 2019, achieved around 60 million visits, reflecting increased health awareness. These efforts contributed to a reduction in advanced cancer cases (stages III and IV) to reach 29 percent. State funding for cancer treatment doubled from 1.8 billion Egyptian pounds in 2020-2021 to 3.6 billion pounds in 2023-2024, along with ongoing investment in oncology infrastructure. Regarding hepatitis C, the report stated that Egypt was the first country to attain the World Health Organization's 'Gold Level' classification in October 2023, reflecting a commitment to reducing infection and mortality rates, and is a step toward complete disease elimination before 2030. Regarding HIV/AIDS, the report indicated that Egypt's prevalence rate is lower than the regional average and highlighted the provision of free antiretroviral treatment to all patients through an extensive network of specialized government centers, with no interruptions in drug availability over the past six years, demonstrating the sustainability of the healthcare system.
